Loading stock data…
Crinetics Pharmaceuticals (CRNX)
$36.94+0.24 (+0.65%)
After Hours$36.94+0.00 (+0.00%)· Last close Jun 29
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Crinetics Pharmaceuticals, Inc. in the Healthcare sector is trading at $36.94 with a market capitalization of $3.6B. Wall Street consensus targets $83.14 (14 analysts), implying a +125.1% move over the next 12 months. The stock is currently 36% below its 52-week high of $57.99, remaining 11.5% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +125.1% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $10.73M↑ | $6.16M↑ | $143,000↓ | $1.03M↑ | $361,000 |
| Gross Profit | $10.53M | — | — | — | $361,000 |
| Operating Income | -$140.38M↓ | -$133.67M↑ | -$142.59M↓ | -$129.11M↓ | -$111.41M |
| Net Income | -$127.84M↓ | -$122.81M↑ | -$130.09M↓ | -$115.64M↓ | -$96.77M |
Peer Comparison
JNJUNHPFE
Fundamentals
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidat...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$3.64B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-38.76%
Volume
Today's trading volume
825,275
Recent News
3 Under-the-Radar Biotech Takeover Targets for the Next Pharma Buying Spree
Big pharma is hunting again, and patent cliffs are forcing buyers to overpay or miss out. Three mid-cap biotechs have quietly positioned themselves as prime acquisition targets, but only one offers the rare combination of a depressed valuation and a commercial product already gaining ground.
Leerink Upholds Outperform Rating for Crinetics Pharmaceuticals (CRNX)
Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) is one of the 10 best mid-cap stocks that could double your money. Based on consensus estimates, as of June 12, the stock offers more than 159% upside potential at the current level. On June 11, Leerink analyst Joseph Schwartz maintained an Outperform rating on Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) following a […]
Crinetics Pharmaceuticals (CRNX) is One of the Best AI Driven Biotech Stocks, Here is Why
Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) is one of the 10 best AI driven biotech stocks to invest in. As of the June 5 close, Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) had a strongly bullish consensus sentiment. Based on a 1-year target price of $88.14, the stock offers an upside potential of more than 167%% at the prevailing level. […]
A Look At Crinetics Pharmaceuticals (CRNX) Valuation As New Endocrine Data Heads To ENDO 2026
Crinetics Pharmaceuticals (CRNX) is back in focus after announcing that new clinical data for PALSONIFY and investigational therapy atumelnant will be presented at ENDO 2026, highlighting ongoing work in endocrine disorders. See our latest analysis for Crinetics Pharmaceuticals. The stock is trading at US$33.09 after a 1-day share price return of 1.47%. Recent momentum has softened, with the 30-day share price return down 19.78%, even as the 3-year total shareholder return is 49.73%. This...
What Do Analysts Say About Crinetics Pharmaceuticals (CRNX)?
With an analyst consensus upside of 126.9%, Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) ranks among the under-the-radar stocks with massive upside for 2026. Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) drew fresh analyst attention after multiple updates tied to the rollout of PALSONIFY and the company’s broader endocrine pipeline. On May 11, 2026, Oppenheimer lowered its price target on Crinetics […]